Navigation Links
Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
Date:6/22/2013

PARIS, June 22, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the first Phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus® (insulin glargine [rDNA origin] injection). The company also announced topline results of a second Phase 3 study (EDITION II) for new insulin U300 that also demonstrated similar blood sugar reduction while fewer patients experienced night-time low blood sugar events compared with Lantus®.

(Logo: http://photos.prnewswire.com/prnh/20110624/NY25833LOGO )

These results are from EDITION I and EDITION II respectively and are part of the EDITION Phase 3 clinical program evaluating the efficacy and safety of the investigational new insulin U300 in people with diabetes.  The EDITION I data was presented at the 73rd Scientific Sessions of the American Diabetes Association.

"To properly manage diabetes, it is critical to control blood sugar and to reduce the risk of low blood sugar events, especially at night," said Matthew Riddle, Professor of Medicine, Division of Endocrinology/Diabetes/Clinical Nutrition, Oregon Health and Science University, U.S., and Principal Investigator for the EDITION I study. "I am encouraged by these findings, and look forward to the results of the full Phase 3 EDITION program, which will further reveal how this investigational basal insulin may help people living with diabetes."

EDITION IAs the first study of the EDITION Phase 3 program, EDITION I evaluated the efficacy and safety of investigational new insulin U300, vs. Lantus® in people with type 2 diabetes using basal pl
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
2. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
3. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
4. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
5. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
6. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
7. NextBio Announces Translational Medicine Partnership with Sanofi
8. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
9. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... in New York, NY on ... James Sapirstein , Chief Executive Officer, ... his live presentation and will be available to participate ...
(Date:7/1/2015)... Pa. , July 1, 2015 Precyse, ... and education, announced today that, as part of its ... an agreement to be acquired by investment firm Pamplona ... private equity investors, Altaris Capital Partners and NewSpring Capital, ... in 1999, has assisted nearly 5,000 healthcare facilities and ...
(Date:7/1/2015)... DUBLIN , June 24, 2015 ... has announced the addition of the "2015 ... to their offering. This new 175-page ... market segments, including diabetes (strips and meters), pregnancy, ... dynamics, size, growth, regulatory requirements, technologies, and competitive ...
Breaking Medicine Technology:ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 32015 Strategies in the Home/Self Testing Market 2
... Instruments Incorporated (TI) (NASDAQ: TXN ) today ... with five new fully integrated AFEs for portable biopotential ... AFEs are the first to offer 16- and 24-bit ... power consumption by more than 94 percent compared to ...
... April 4, 2012  UCB (Euronext Brussels: UCB) and Amgen ... of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical ... "We look forward to working with UCB on ... Harper, M.D., executive vice president of Research and Development ...
Cached Medicine Technology:TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 2TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 3TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 4TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 5UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 2UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 3UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 4UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 5UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 6UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 7
(Date:7/1/2015)... ... , ... For decades, researchers in the genetics field have theorized that the ... changing after development in the womb. Now, researchers from the Icahn School of Medicine ... life – a process which helps to switch genes on and off. This histone ...
(Date:7/1/2015)... NY (PRWEB) , ... July 01, 2015 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – today announced that they will welcome four new members to their industry ...
(Date:7/1/2015)... ... 2015 , ... Ormco Corporation, a leading manufacturer and provider ... for a Lifetime Foundation (S4L) fundraising event held at the 14th Annual Damon ... in its mission to provide free quality orthodontic care to individuals with financial ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. Construction of the ... DIC Group’s U.S. Spirulina* production base, began in May 2014. After commissioning, commercial ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... The Collaborative ... the New York Community Trust. The grant will allow CCF to improve quality of ... practices. , CCF was formed to respond to many changes in New York’s Medicaid ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3
... (Nov. 20, 2010) Columbia University Medical Center will ... researcher who has made important advances in understanding the ... disease. A promising young investigator at Columbia will also ... for disordered lipid metabolism in diabetes. ...
... By Madonna Behen HealthDay Reporter , FRIDAY, ... rising on U.S. college campuses, college officials are trying various ... that targeted off-campus boozing shows some promise, researchers say. ... California cut the level of heavy drinking at private parties ...
... Houston (UH) physicists are using complex computer simulations to ... malfunctioning, may cause Alzheimer,s and cancer. Margaret ... Samiotakis, a physics Ph.D. student, described their findings in ... kinase (PGK) are strongly perturbed by macromolecular crowding," published ...
... construct an online interactive world map which gives stark facts ... and following the birth of their child. Social scientists ... collaboration with the White Ribbon Alliance for Safe Motherhood and ... excess of 160,000 called ,The Atlas of Birth, which also ...
... News) -- People who develop gastroenteritis from E. coli-contaminated ... pressure, kidney problems and heart disease later in life, ... the Walkerton Health Study, which evaluated the long-term health ... (commonly known as stomach flu) in May 2000 after ...
... (HealthDay News) -- Among patients with kidney disease in ... some Hispanics, get sicker faster than whites do, researchers ... chronic kidney disease has been established," study co-author Dr. ... Francisco, said in a news release from the American ...
Cached Medicine News:Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 2Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 3Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 4Health News:Outreach, Enforcement Can Curb College Kids' Drinking: Study 2Health News:Outreach, Enforcement Can Curb College Kids' Drinking: Study 3Health News:UH physicists study behavior of enzyme linked to Alzheimer's, cancer 2Health News:UH physicists study behavior of enzyme linked to Alzheimer's, cancer 3Health News:Online map of maternal health to inform world leaders 2Health News:E. Coli Could Have Long Term Effect on Heart 2Health News:Race Seems to Impact Rate of Kidney Function Decline 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: